Brief: Inhibikase Therapeutics Announces Publication Highlighting Results From Its Phase 1 Studies
29/01/2024 14:12
Jan 29 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES PUBLICATION HIGHLIGHTING
RESULTS FROM ITS PHASE 1 STUDIES WITH RISVODETINIB
* INHIBIKASE THERAPEUTICS INC - DATA DEMONSTRATED THAT
RISVODETINIB WAS WELL TOLERATED UP TO 7 DAYS OF DAILY DOSING
Source text for Eikon: ID:nGNX1k7NWL
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share